Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Preferred Stock Liabilities (2020 - 2025)

Marimed (MRMD) has disclosed Preferred Stock Liabilities for 6 consecutive years, with $14.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Preferred Stock Liabilities fell 22.5% to $14.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.7 million, a 22.5% decrease, with the full-year FY2024 number at $19.0 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities was $14.7 million for Q3 2025 at Marimed, roughly flat from $14.7 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $37.7 million in Q1 2021 to a low of $14.7 million in Q1 2025.
  • A 5-year average of $27.3 million and a median of $21.9 million in 2023 define the central range for Preferred Stock Liabilities.
  • Peak YoY movement for Preferred Stock Liabilities: surged 156.2% in 2021, then crashed 49.64% in 2023.
  • Marimed's Preferred Stock Liabilities stood at $37.7 million in 2021, then changed by 0.0% to $37.7 million in 2022, then plummeted by 49.64% to $19.0 million in 2023, then changed by 0.0% to $19.0 million in 2024, then decreased by 22.5% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Preferred Stock Liabilities are $14.7 million (Q3 2025), $14.7 million (Q2 2025), and $14.7 million (Q1 2025).